Anti-PD1/PDL1 Immunotherapy (All Cancer)

This course explores the efficacy of Anti-PD1/PDL1 immunotherapy within various cancer types.

“Despite advances in research, the prognosis of patients with cancer (particularly late-stage disease) is disappointing. In recent years, the use of immune checkpoint inhibitors (ICIs) has further optimized the treatment patterns for multiple types of cancers. Programmed cell death 1 (PD1): programmed cell death 1 ligand 1 (PDL1), and cytotoxic T lymphocyte-associated protein 4 (CTLA4): B-lymphocyte activation antigen B7 (B7-1; also termed CD80) are the most extensively studied immune checkpoints for cancer immunotherapy.”

https://www.frontiersin.org/articles/10.3389/fimmu.2022.862084/full#f1